Stiefel Laboratories Inc, the world’s largest independent pharmaceutical company specialising in dermatology, has announced that Gavin Corcoran, MD, FACP, has been promoted to the newly created position of chief scientific officer.
The role will involve overseeing global scientific and operational activities related to product development and support; medical and scientific affairs; clinical and pre-clinical research; pharmacovigilance; portfolio planning; and regulatory affairs.
Brent Stiefel, executive vice president, Global Corporate Development and Product Portfolio said: “Gavin’s promotion is a testament to the wonderful work he has done for Stiefel since he came on board.
“We chose Gavin to lead our R&D division because his vast experience along with his keen understanding of the industry arms him with the insight that will improve today’s skin treatments and develop tomorrow’s solutions.”
The accomplishments Stiefel references include Corcoran establishing global R&D headquarters in Research Triangle Park, North Carolina; helping to lead integration following the acquisition of Connetics Corporation; overseeing R&D facilities on four continents; and strengthening the alignment of the R&D objectives and structure with the strategic direction of the business.
The South African specialises in internal medicine and infectious diseases and has professional experience in private practice, academia and the pharmaceutical industry.
His extensive pharmaceutical experience includes clinical research and regulatory leadership positions at Bayer, Schering-Plough and Amgen. In addition, he has successfully worked on drug development in a variety of fields, including anti-infectives, diabetes and dermatological infections.
Copyright © PA Business 2008